Diastereoselective and green synthesis of novel Hexahydro Imidazo [1,2-a] pyrimidine, from Azlactones, Brimonidine and Clonidine Authors: Keikavoos Rahmati, Ali A Mohammadi, Vahid Amani, Mohammad Reza Halvgar Published: 2026 ABSTRACT AbstractAn efficient direct domino approach has been developed for the diastereoselective synthesis of novel hexahydroimidazo[1,2-a]pyrimidine-6-yl acetamides. This synthesis involves a domino Michael addition/cyclization reaction of azlactones with brimonidine (used as eye drops for treating open-angle glaucoma) and clonidine (used to treat high blood pressure and attention deficit hyperactivity disorder). The reaction is catalyzed by glacial acetic acid (GAA), which acts as a mild organocatalyst in a metal-free environment, adhering to green chemistry principles by utilizing green solvent (EtOH). Additionally, the transformation proceeds with an atom economy of 100%. The imidazo[1,2-a]pyrimidine moiety plays a crucial role as a benzodiazepine receptor agonist, antiviral, antibacterial, antifungal agent, and calcium channel blocker. This reaction has been performed for the first time, and all synthesized compounds are novel. Their structures were confirmed by single-crystal X-ray crystallography, as well as IR, 1H NMR, 13C NMR spectroscopy, and LCMS analysis. Surprisingly, this reaction was diastereoselective, yielding cis-imidazo[1,2-a]pyrimidines 4b–g and trans-imidazo[1,2-a]pyrimidines 6a-g in cyclocondensation reaction of brimonidine 1 or clonidine 2 with azlactones 3a-g, respectively.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-55668-6.Keywords: Imidazo[1,2-a]pyrimidine; Azlactone; Brimonidine; Clonidine; Diasteroselectivity; Green chemistrySubject terms: Chemistry, Drug discovery Introduction Heterocyclic compounds are an important class of organic compounds, especially nitrogen-containing heterocycles such as imidazo[1,2-a]pyrimidines. These compounds have significant biological and pharmacological activities. Imidazo[1,2-a]pyrimidines and dihydropyridines have been reported in structure of medicines with anti-inflammatory1, antibacterial2,3, antidiarrheal4, antitumor5, antitubercular6,7, antiprotozoal8, antioxidant9, antifungal10,11, antimicrobial12–14, antiviral15, and calcium channel blocker16 properties. Numerous synthetic routes for imidazo[1,2-a]pyrimidine skeletons have been reported. These routes include 1,3-dipolar cyclization17, condensation reactions with β-ketoacetals18,19, Baylis-Hillman reaction20,21, pseudo-Michael reaction22–24, Click reaction25,26, and Biginelli multicomponent reactions27. However, these investigations remain in early stages. Brimonidine 1 is used as an eye drop to treat open-angle glaucoma28,29 or ocular hypertension, as well as facial skin redness (erythema) in rosacea in gel form. It treats redness by vasoconstriction, acting as an α2-adrenergic agonist30. α2 Agonists inhibit adenylate cyclase activity via G protein-coupled receptor activation, causing vasoconstriction. Clonidine 2 is used to treat hypertension, attention deficit hyperactivity disorder, drug withdrawal symptoms, menopausal flushing, diarrhea, and certain pain conditions31. It lowers blood pressure by stimulating α2 receptors in the brain, relaxing arteries32. It also reduces pulse rate and serum concentrations of renin, aldosterone, and catecholamines (Fig. 1)33. Brimonidine 1 and Clonidine 2. Recently, we reported the synthesis and biological evaluation of nitrogen-containing compounds34–38, including tetrahydropyridines, spiro[indene-1,2′-quinazolin]-4′(3′H)-ones, and tetra-amide derivatives. Methods In our ongoing work on the preparation of bioactive nitrogen-containing heterocyclic compounds39,40, we designed a synthesis of novel imidazo[1,2-a]pyrimidines catalyzed by glacial acetic acid as an organocatalyst (Scheme 1). Synthesis of cis-imidazo[1,2-a]pyrimidine 4a. A mixture of brimonidine 1 and azlactone 3a41–45 in ethanol was stirred at reflux in the presence of a catalytic amount of GAA, completing the reaction within 3.5 h. Workup afforded imidazo[1,2-a]pyrimidine 4a in 84% yield (Scheme 1). Notably, the reaction was diastereoselective, producing the cis-imidazo[1,2-a]pyrimidine 4a. After screening several catalysts [HBr, HCl, p-toluenesulfonic acid (PTSA), alum, Et3N, and CH3CO2H], solvents (CH3CN and EtOH), and temperatures (rt, 50 °C, reflux), ethanol, CH3CO2H, and reflux temperature were found optimal for promoting the reaction with good yields (Table 1). Table 1Effect of solvent, temperature, and catalyst on the time and yield of the reaction of brimonidine 1 (1 mmol) and azlactone 3a (1 mmol).EntryaSolventTemp. (°C)Catal. (H2O%)Mol (%)Time (h)Yield (%)b 1 CH3CNrt., 50, Reflux--24- 2 EtOHr.t, 50, Reflux--24- 3 EtOH50, RefluxHBr (50)301.5(82)c 4 EtOH50, RefluxHBr (50)202(79)c 5 EtOH50, RefluxEt3N (20)208(66)c 6 EtOH50, RefluxHCl (63)302.5(74)c 7 CH3CN50CH3CO2H (30)202.5(75)c 8 CH3CN50CH3CO2H (0)203.559d 9 EtOH50CH3CO2H (0)20461d 10 EtOHRefluxCH3CO2H (0)203.584d 11 EtOH or CH3CNRefluxPTSA (0)205Traceda For all reactions, brimonidine 1 and azlactone derivatives 3a(1.0 mmol), 0–30 mol% of catalyst, and rt - reflux in ethanol or CH3CN were used.b Yield of pure isolated product based on brimonidine. Reported Yield is the average of three independent experiments differing about ± 1%.c2-Benzamido-3-phenylacrylic acid 5a.dHexahydroimidazo[1,2-a]pyrimidine acetamide 4a. Effect of solvent, temperature, and catalyst on the time and yield of the reaction of brimonidine 1 (1 mmol) and azlactone 3a (1 mmol). a For all reactions, brimonidine 1 and azlactone derivatives 3a(1.0 mmol), 0–30 mol% of catalyst, and rt - reflux in ethanol or CH3CN were used. b Yield of pure isolated product based on brimonidine. Reported Yield is the average of three independent experiments differing about ± 1%. c2-Benzamido-3-phenylacrylic acid 5a. dHexahydroimidazo[1,2-a]pyrimidine acetamide 4a. Using catalysts such as HBr, HCl, CH3CO2H, or Et3N in aqueous media with EtOH or CH3CN, 2-benzamido-3-phenylacrylic acid 5a was formed in 66–82% yield (Scheme 2, Table 1 entries 3–7)46,47. Encouraged by this, the reaction was extended to various brimonidine 1 and azlactone derivatives 3b–g in ethanol under reflux with catalytic GAA, furnishing cis-imidazo[1,2-a]pyrimidines 4b–g with diastereoselectivity and good yield (Table 2). Structures of 4a–g were confirmed by IR, 1H NMR, 13C NMR, LCMS, and single-crystal X-ray crystallography. The summarized results are listed in Table 2. Table 2Synthesis of N-((6 S,7R)-8-(5-bromoquinoxalin-6-yl)-5-oxo-7-phenyl-2,3,5,6,7,8- hexahydroimidazo[1,2-a]pyrimidin-6-yl)acetamide (4a-g). Entry R 1 a Time (h)m.p. (°C)Yield (%)bdr (%)cis/transc 4a C6H53.5240–24284100/0 4b 4-CH3C6H43.5237–24078100/0 4c 4-ClC6H45.5234–23675100/0 4d 4-NO2C6H45242–24579100/0 4e 4-HOC6H46266–27082100/0 4f C4H3S5239–24188100/0 4 g 4-BrC6H48235–23780100/0 a For all reactions, brimonidine 1 and azlactone derivatives 3 (1.0 mmol), 20 mol% of GAA, and reflux in ethanol were used.b Yield of pure isolated product based on brimonidine. Reported Yield is the average of three independent experiments differing about ± 1%.c No minor diastereomer detected by ¹H NMR under our analysis conditions. Synthesis of N-((6 S,7R)-8-(5-bromoquinoxalin-6-yl)-5-oxo-7-phenyl-2,3,5,6,7,8- hexahydroimidazo[1,2-a]pyrimidin-6-yl)acetamide (4a-g). a For all reactions, brimonidine 1 and azlactone derivatives 3 (1.0 mmol), 20 mol% of GAA, and reflux in ethanol were used. b Yield of pure isolated product based on brimonidine. Reported Yield is the average of three independent experiments differing about ± 1%. c No minor diastereomer detected by ¹H NMR under our analysis conditions. All new products 4a–g exhibited two signals in the 1H NMR spectrum (singlet, doublet or doublet of doublet) near 5.0–5.5 ppm (J = 0–9 Hz) and 5.4–6.1 ppm (J = 3–9 Hz), corresponding to H-5 and H-8 hydrogens, respectively (Table 3). Single-crystal X-ray data showed a torsion angle (H9–C8–C5–H10) of 49.0 (6)°, consistent with Karplus equation48(Fig. 2). Combination of 1H NMR coupling constants and torsional angles from X-ray crystallography data confirmed cis stereochemistry for imidazo[1,2-a]pyrimidine 4a-g. IR spectra showed NH stretching at 3295–3350 cm− 1 and two C = O stretches at 1780–1800 and 1680–1750 cm− 1. Table 3Hydrogen stereoisomer coupling constants data for derivatives 4a-g.Compoundδ H5 (ppm)MultiplicityJ (Hz)δ H8 (ppm)MultiplicityJ (Hz) 4a 4b 5.53ddJ = 6, J = 65.18d65.50ddJ = 9, J = 95.12d6 4c 5.53ddJ = 6, J = 65.18d6 4d 5.54ddJ = 9, J = 96.06d9 4e 5.46s-5.03d3 4f 5.53ddJ = 6, J = 65.43d6 4 g 5.54d65.19d6 Hydrogen stereoisomer coupling constants data for derivatives 4a-g. 4a 4b The molecular structure of 4 g with 30% probability displacement ellipsoids and atom-numbering scheme. The dimethyl sulfoxide molecule has been removed for clarity. Figure was drawn with the Mercury 2.4 software49. The proposed mechanism for the synthesis of products 4a-g is illustrated in Scheme 3. Synthesis imidazo[1,2-a]pyrimidine 4a and 2-benzamido-3-phenylacrylic acid 5a. This method was also applied to clonidine 2, where azlactone derivatives 3a–g reacted under similar conditions to afford trans-imidazo[1,2-a]pyrimidine derivatives 6a–g (Table 4). Table 4Synthesis of trans-imidazo[1,2-a]pyrimidine 6. Entry R 1 a Time (h)m.p. (°C)Yield (%)bdr (%)ccis/trans 6a C6H53286–289880/100 6b 4-CH3C6H43286–289850/100 6c 4-ClC6H43287–290830/100 6d 4-NO2C6H42.5262–264850/100 6e 4-HOC6H44241–243830/100 6f C4H3S5279–281840/100 6 g 4-BrC6H45277–279820/100 a For all reactions, clonidine 2 and azlactone derivatives 3 (1.0 mmol), 20 mol% of GAA, and reflux in ethanol were used.b Yield of pure isolated product based on brimonidine. Reported Yield is the average of three independent experiments differing about ± 1%.c No minor diastereomer detected by ¹H NMR under our analysis conditions. Synthesis of trans-imidazo[1,2-a]pyrimidine 6. a For all reactions, clonidine 2 and azlactone derivatives 3 (1.0 mmol), 20 mol% of GAA, and reflux in ethanol were used. b Yield of pure isolated product based on brimonidine. Reported Yield is the average of three independent experiments differing about ± 1%. c No minor diastereomer detected by ¹H NMR under our analysis conditions. Surprisingly, this reaction yielded trans-imidazo[1,2-a]pyrimidines 6a-g. In the 1HNMR spectrum all new products 6a-g, it was observed that two protons H-5 and H-8 appeared close to 4.8–4.9 ppm (dd, J = 3–12 Hz) and 5.3–5.7 ppm (d, J = 12 Hz), respectively (Table 5). The single crystal X-ray crystallography shows the close proximity of these two hydrogen atoms with a torsion angle (H5–C5–C8–H9) was 168.9 (7)°, consistent with Karplus equation48(Fig. 3). Combination of 1H NMR coupling constants and torsional angles from X-ray crystallography data confirmed trans stereochemistry for imidazo[1,2-a]pyrimidine 6a-g (Scheme 4, Table 4). Table 5Hydrogen stereoisomer coupling constants data for derivatives 6a-g.Compoundδ H5 (ppm)MultiplicityJ (Hz)δ H8 (ppm)MultiplicityJ (Hz) 6a 4.93ddJ = 9, J = 95.48d12 6b 4.83ddJ = 9, J = 125.45d12 6c 4.92ddJ = 9, J = 125.48d12 6d 4.99ddJ = 9, J = 95.65d12 6e 4.87ddJ = 9, J = 125.34d12 6f 4.81ddJ = 9, J = 125.78d12 6 g 4.90ddJ = 3, J = 95.47d12 Hydrogen stereoisomer coupling constants data for derivatives 6a-g. The asymmetric molecular structure of 6d with 30% probability displacement ellipsoids and atom-numbering scheme. Figure was drawn with the Mercury 2.4 software49. Proposed mechanism of the reaction of brimonidine 1 and azlactone 3 for preparation of cis-imidazo[1,2-a]pyrimidine 4. In addition, the atom economy (AE) for the reported domino Michael/cyclization reaction is 100%, as all atoms from the starting materials are incorporated into the product. AE was calculated using the formula: This highlights the high efficiency and shows ideal stoichiometric metric (Table 6). Table 6Atom economy for cis-imidazo[1,2-a]pyrimidine 4a–g and trans-imidazo[1,2-a]pyrimidine derivatives 6a–g.EntryMolecular weight ofreactantsMolecular weight ofreactantsSum of molecular weight ofreactantsMolecular weight of theproductAE (%) 1 1(C11H10BrN5)3a(C11H9NO2)(C22H19BrN6O2)4a( C22H19BrN6O2)100 2 1(C11H10BrN5)3b(C12H11NO2)(C23H21BrN6O2)4b(C23H21BrN6O2)100 3 1(C11H10BrN5)3c(C11H8ClNO2)(C22H18BrClN6O2)4c(C22H18BrClN6O2)100 4 1(C11H10BrN5)3d(C11H8N2O4)(C22H18BrN7O4)4d(C22H18BrN7O4)100 5 1(C11H10BrN5)3e(C11H9NO3)(C22H19BrN6O3)4e(C22H19BrN6O3)100 6 1(C11H10BrN5)3f(C9H7NO2S)(C20H17BrN6O2S)4f(C20H17BrN6O2S)100 7 1(C11H10BrN5)3 g(C11H8BrNO2)(C22H18Br2N6O2)4 g(C22H18Br2N6O2)100 8 2(C9H9Cl2N3)3a(C11H9NO2)(C20H18Cl2N4O2)6a(C20H18Cl2N4O2)100 9 2(C9H9Cl2N3)3b(C12H11NO2)(C21H20Cl2N4O2)6b(C21H20Cl2N4O2)100 10 2(C9H9Cl2N3)3c(C11H8ClNO2)(C20H17Cl3N4O2)6c(C20H17Cl3N4O2)100 11 2(C9H9Cl2N3)3d(C11H8N2O4)(C20H17Cl2N5O4)6d(C20H17Cl2N5O4)100 12 2(C9H9Cl2N3)3e(C11H9NO3)(C20H18Cl2N4O3)6e(C20H18Cl2N4O3)100 13 2(C9H9Cl2N3)3f(C9H7NO2S)(C18H16Cl2N4O2S)6f(C18H16Cl2N4O2S)100 14 2(C9H9Cl2N3)3 g(C11H8BrNO2)(C20H17BrCl2N4O2)6 g(C20H17BrCl2N4O2)100 Atom economy for cis-imidazo[1,2-a]pyrimidine 4a–g and trans-imidazo[1,2-a]pyrimidine derivatives 6a–g. Proposed mechanism of the reaction of clonidine 2 and azlactone 3 for preparation of trans-imidazo[1,2-a]pyrimidine 6. The X-ray crystallographic analysis of compounds 4 g and 6d was performed to confirm their molecular structures, as detailed in the Supplementary Information (Tables S1, S2, Figs. S1–S4). Compound 4 g crystallizes in the triclinic Pī space group with a dimethyl sulfoxide solvate, while 6d, a twinned crystal, adopts the monoclinic P21/c space group. Due to instrumental limitations, data were collected at 293 K with a modest θ(max) ≈ 25°, and the twinned nature of 6d necessitated a higher I/σ(I) cutoff (threshold multiplier = 4.0) and the use of DELU/SIMU restraints (approximately 576 for 6d) to ensure reliable refinement, with a twin law [1 0 2] and BASF ≈ 0.46 applied for 6d. The observed/unique reflection ratios (4 g: 49%, Rint = 0.1069; 6d: 28%, Rint = 0.1850) and goodness-of-fit values (4 g: S = 0.769; 6d: S = 0.659) reflect the weak data quality, particularly for 6d, where twinning and low crystal quality limited precision (C-C bond precision ≈ 0.0082 Å for 4 g). Absorption corrections were applied using numerical integration methods, though full structure factors for 4 g were not included due to data constraints. A long H···A contact (H21···O2 = 2.65 Å) in 4 g was retained after verifying geometry, and the DMSO solvate in 4 g was modeled with appropriate restraints. These crystallographic data, while confirming the connectivity and stereochemistry of the synthesized compounds, are supplementary to the primary focus of this study on the diastereoselective synthesis of hexahydro imidazo[1,2-a]pyrimidines, with limitations in data quality attributed to equipment constraints and the absence of low-temperature data collection. These crystallographic data are of limited precision and used solely for confirmation of connectivity and stereochemistry, not for detailed conformational or metric analysis. The observed divergent diastereoselectivity in the cyclization reactions cis products with brimonidine and trans products with clonidine can be attributed to steric and electronic effects during ring closure. The measured dihedral angles (H5–C5–C8–H9 ca. 169° for trans; H9–C8–C5–H10 ca. 49° for cis) and the corresponding J-coupling constants support the proposed stereochemical rationale, highlighting the influence of substituent interactions on the preferred cyclization pathway. Therefore, these reactions are diastereoselective, yielding exclusively the cis or trans products depending on the starting compound. Experimental and subject details The progress of the reactions was monitored by thin layer chromatography (TLC) using Merck silica gel (70–230 mesh) plates. IR spectra were recorded in KBr pellets on a Shimadzu IR 470 spectrophotometer. 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra were determined on a Q.One AS400 and 1H NMR (300 MHz) and 13C NMR (75 MHz) spectra were determined on a Bruker 300 DRX Avance instrument. Single crystal data were collected on diffractometer equipped with a STOE IPDS/2T imaging plate detector, T = 293(2) K, MoKa radiation (µMoKa = 0.71073 Å), graphite monochromator, Structure solution by direct methods, full-matrix-least-squares refinement against F. Mass of the pure isolated products were determined by LCMS-2010 A Shimadzu instrument. General procedure for the preparation of compounds 4 (a-g) and 6 (a-g) A mixture of brimonidine 1 or clonidine 2 (1mmol), azlactones 3a-g (1mmol), and glacial acetic acid (20 mol%) in EtOH (4 mL, 99–100% purity) in a 50 mL flask was stirred under reflux (78–80 °C) for the times indicated in Tables 2 and 4. Reaction progress was monitored by TLC (ethyl acetate/ n-hexane, 1:2, for 4a Rf = 0.15). After completion of the reaction, the solvent was evaporated at room temperature, and the resulting solid was filtered. The crude product was washed with EtOH: Water (1:1, 2 × 5 mL) to yield a white solid. The washed products were characterized as was obtained and no further purification or recrystallization was needed. Conclusions We have described a stereoselective strategy and convenient green synthesis for the preparation of cis-imidazo[1,2-a]pyrimidine and trans-imidazo[1,2-a]pyrimidines in cyclocondensation reaction of brimonidine 1 or clonidine 2 (1mmol) and azlactones 3a-g (1mmol), respectively. The reactions are performed in EtOH, 20 mol% glacial acetic acid, mild, and one-pot conditions with simple work-up improving sustainablity. This method offers several advantages including high yield of products, stereoselective strategy, no need for metal catalysts, EtOH as a relatively benign green solvent, with atom 100% atom economy, and easy experimental workup procedure, which makes it a useful process for the synthesis of cis-imidazo[1,2-a]pyrimidine and trans-imidazo[1,2-a]pyrimidine derivatives. Moreover, starting from biologically active medicines such as brimonidine and clonidine provides a basis for potential future bioevaluation of these novel derivatives. Identification and spectral data N-((6 S,7R)-8-(5-Bromoquinoxalin-6-yl)-5-oxo-7-phenyl-2,3,5,6,7,8-hexahydroimidazo[1,2-a]pyrimidin-6-yl)acetamide (4a) White solid, MP: 240–244 °C, IR(KBr) (νmax/cm− 1); 3262(NH), 3032, 2926, 2873, 1701(C = O), 1647(C = O), 1534, 1492, 1408, 1272, 697; 1H NMR (300 MHz, DMSO-d6) δH (ppm) 1.86 (3 H, s, CH3), 3.67 (1H, m, CH2), 3.79 (1H, m, CH2), 3.90 (1H, m, CH2), 4.04 (1H, m, CH2), 5.18 (1H, d, J = 6 Hz, CH), 5.53 (1H, dd, J = 6 Hz, J = 6 Hz, CH), 7.11–7.20 (2 H, m, Ar-H), 7.30–7.38 (4 H, m, 3Ar-H, 1NH), 7.97–8.06 (2 H, m, Ar-H), 9.02–908 (2 H, m Ar-H); 13C NMR (75 MHz, DMSO-d6) δC (ppm) 22.7, 42.4, 44.6, 50.9, 53.4, 62.3, 125.0, 128.1, 129.0, 129.4, 132.2, 136.2, 140.9, 142.3, 142.4, 146.9, 147.1, 150.3, 163.7, 170.6. LCMS m/z: 478 [M + H]+, 480 [M + H]2+. Anal.calcd. for: C22H19BrN6O2; C, 55.13; H, 4.00; N, 17.53%. Found: C, 55.01; H, 3.90; N, 17.42%. N-((6 S,7R)-8-(5-Bromoquinoxalin-6-yl)-5-oxo-7-ptolyl2,3,5,6,7,8-hexahydroimidazo[1,2-a]pyrimidin-6-yl)acetamide (4b) White solid, MP: 237–240 °C, IR (KBr) (νmax/cm− 1); 3402, 3242(NH), 2967, 2885, 1708 (C = O), 1646 (C = O), 1492, 1407, 1273; 1H NMR (400 MHz, DMSO-d6) δH (ppm), 1.86 (3 H, s, CH3), 2.28 (3 H, s, CH3), 3.66 (1H, m, CH2), 3.78 (1H, m, CH2), 3.87 (1H, m, CH2), 4.03 (1H, m, CH2), 5.12 (1H, d, J = 6 Hz, CH), 5.50 (1H, dd, J = 9 Hz, J = 9 Hz, CH), 6.98–6.98 (2 H, m, Ar-H), 7.16–7.18 (2 H, m, Ar-H), 7.41–7.43(1H, br, NH), 7.97–7.99 (2 H, m, Ar-H), 9.01–9.07 (2 H, m, Ar-H); 13C NMR (100 MHz, DMSO-d6) δC (ppm), 20.6, 22.2, 44.1, 50.4, 52.9, 62.6, 124.4, 127.5, 128.5, 129.5, 131.7, 132.7, 137.8, 140.4, 141.9, 142.0, 146.5, 146.6, 149.8, 163.3, 170.0. LCMS m/z: 492 [M + H]+, 494 [M + H]2+. Anal.calcd. for: C23H21BrN6O2; C, 55.99; H, 4.29; N, 17.03%. Found: C, 55.86; H, 4.18; N, 16.91%. N-((6 S,7R)-8-(5-Bromoquinoxalin-6-yl)-7-(4-chlorophenyl)-5-oxo-2,3,5,6,7,8-hexahydroimidazo[1,2-a]pyrimidin-6-yl)acetamide (4c) White solid, MP: 233–235 °C, IR (KBr) (νmax/cm− 1); 3608, 3270(NH), 3044, 2906, 1682 (C = O), 1647(C = O), 1488, 1408, 1269, 1010; 1H NMR (300 MHz, DMSO-d6) δH (ppm) 1.85 (3 H, s, CH3), 3.66 (1H, m, CH2), 3.77 (1H, m, CH2), 3.88 (1H, m, CH2), 4.03 (1H, m, CH2), 5.18 (1H, d, J = 6 Hz, CH), 5.53 (1H, dd, J = 6 Hz, J = 6 Hz, CH), 7.11–7.15 (2 H, m, Ar-H), 7.41–7.44 (3 H, m, 2Ar-H, 1NH), 8.00-8.04 (2 H, m, Ar-H), 9.00-9.06 (2 H, m, Ar-H); 13C NMR (75 MHz, DMSO-d6) δC (ppm); 22.6, 44.7, 50.9, 53.1, 61.7, 125.0, 129.2, 129.4, 130.1, 132.3, 133.7, 135.2, 140.9, 142.1, 142.5, 147.0, 150.2, 163.5, 170.5. LCMS m/z: 512 [M + H]+, 514 [M + H]2+. Anal.calcd. for: C22H18BrClN6O2; C, 51.43; H, 3.53; N, 16.36%. Found: C, 51.30; H, 3.39; N, 16.26%. N-((6 S,7R)-8-(5-Bromoquinoxalin-6-yl)-7-(4-nitrophenyl)-5-oxo-2,3,5,6,7,8-hexahydroimidazo[1,2-a]pyrimidin-6-yl)acetamide (4d) White solid, MP: 241–243 °C, IR (KBr) (νmax/cm− 1); 3207 (NH), 2782, 1701 (C = O), 1649 (C = O), 1597, 1478, 1342, 1282, 677; 1H NMR (300 MHz, DMSO-d6) δH (ppm) 1.73 (3 H, s, CH3), 3.82–3.87 (2 H, m, CH2), 4.22–4.28 (2 H, m, CH2), 5.54 (1H, dd, J = 9 Hz, J = 9 Hz, CH), 6.06 (1H, d, J = 9 Hz, CH), 7.11–714 (2 H, d, J = 9 Hz, Ar- H), 7.47–7.50 (2 H, d, J = 9 Hz, Ar-H), 7.72 (1H, br, NH), 8.01–8.10 (2 H, m, Ar-H), 9.04–9.07 (2 H, m, Ar-H); 13C NMR (75 MHz, DMSO-d6) δC (ppm) 21.2, 50.2, 52.6, 53.7, 62.2, 123.8, 125.9, 128.5, 131.5, 132.7, 133.8, 136.5, 140.2, 142.3, 147.6, 150.5, 163.4, 171.4. LCMS m/z: 523 [M + H]+, 525 [M + H]2+. Anal.calcd. for: C22H18BrN7O4; C, 50.40; H, 3.46; N, 18.70%. Found: C, 50.36; H, 3.34; N, 18.56. N-((6 S,7R)-8-(5-Bromoquinoxalin-6yl)7(4-hydroxyphenyl)-5-oxo-2,3,5,6,7,8-hexahydroimidazo[1,2a]pyrimidin6yl)acetamide (4e) White solid, MP: 266–270 °C, IR(KBr) (νmax/cm− 1); 3393 (NH), 2896, 1707(C = O), 1680(C = O), 1644 (C = O), 1494, 1400, 1271; 1H NMR (300 MHz, DMSO-d6) δH (ppm) 1.86 (3 H, s, CH3), 3.66 (1H, m, CH2), 3.77 (1H, m, CH2), 3.88 (1H, m, CH2), 4.02 (1H, m, CH2), 5.03 (1H, d, J = 3 Hz, CH), 5.46 (1H, s, CH), 6.72 (2 H, m, Ar-H), 6.88 (2 H, m, Ar- H), 7.42 (1H, br, NH), 7.93–7.97 (2 H, m, Ar-H), 9.01–9.07(2 H, m, Ar-H), 9.50 (1H, br, OH); 13C NMR (75 MHz, DMSO-d6) δC (ppm) 21.5, 43.4, 52.1, 53.6, 61.0, 124.3, 126.2, 128.1, 130.4, 132.2, 134.4, 135.1, 138.1, 141.1, 147.8, 150.8, 161.9, 169.5. LCMS m/z: 494 [M + H]+, 496 [M + H]2+. Anal.calcd. for: C22H19BrN6O3; C, 53.35; H, 3.87; N, 16.97%. Found: C, 53.22; H, 3.77; N, 16.86%. N((6 S,7R)-8-(5-Bromoquinoxalin-6-yl)-5-oxo-7-(thiophen-2-yl)-2,3,5,6,7,8-hexahydroimidazo[1,2a]pyrimidin-6-yl)acetamide (4f) Bright Brown solid, MP: 239–241 °C, IR(KBr) (νmax/cm− 1); 3432, 3240 (NH), 2886, 1694 (C = O), 1652 (C = O), 1535, 1487, 1410, 1269, 972; 1H NMR (300 MHz, DMSO-d6) δH (ppm) 1.88 (3 H, s, CH3), 3.63–4.11 (4 H, m, 2CH2 ), 5.43 (1H, d,=6 Hz, CH), 5.53 (1H, dd, J = 6 Hz, J = 6 Hz, CH), 6.89–6.99 (2 H, m, Ar- H), 7.47 (1H, d, J = 9 Hz, Ar- H ), 7.59 (1H, d, J = 3 Hz, NH ), 8.00-8.03 (1H, d, J = 9 Hz, Ar- H), 8.20–8.22 (1H, d, J = 6 Hz, Ar- H ), 9.03–9.09 (2 H, m, Ar-H); 13C NMR (75 MHz, DMSO-d6) δC (ppm) 22.7, 44.5, 51.0, 53.9, 59.1, 127.7, 128.9, 131.8, 137.9, 140.9, 142.5, 146.9, 147.1, 149.7, 163.5, 170.6. LCMS m/z: 484 [M + H]+, 486 [M + H]2+. Anal.calcd. for: C20H17BrN6O2S; C, 49.49; H, 3.53; N, 17.32%. Found: C, 49.35; H, 3.42; N, 17.21%. N((6 S,7R)-7-(4-Bromophenyl)-8-(5-bromoquinoxalin-6-yl)-5-oxo-2,3,5,6,7,8 hexahydroimidazo[1,2a]pyrimidin-6-yl)acetamide (4 g) White solid, MP: 234–236 °C, IR (KBr) (νmax/cm-1); 3408, 3244(NH), 2967, 2887, 1708 (C = O), 1647(C = O), 1489, 1409, 1271, 973; 1H NMR (300 MHz, DMSO-d6) δH (ppm) 1.87 (3 H, s, CH3), 3.68 (1H, m, CH2), 3.78 (1H, m, CH2), 3.90 (1H, m, CH2), 4.03 (1H, m, CH2), 5.19 (1H, d, J = 6 Hz, CH), 5.54 (1H, d, J = 6 Hz, CH), 7.07–7.09 (2 H, m, Ar-CH), 7.53–7.56 (3 H, m, 2Ar-H, 1NH), 7.98–8.02 (2 H, m, Ar- H), 9.01–9.06 (2 H, m, Ar-H); 13C NMR (75 MHz, DMSO-d6) δC (ppm) 21.2, 43.7, 50.6, 53.5, 60.8, 124.0, 125.9, 128.5, 131.3, 133.4, 134.5, 135.3, 139.6, 142.7, 148.7, 150.0, 163.8, 170.7. LCMS m/z: 555 [M + H]+, 557 [M + H]2+. Anal.calcd. for: C22H18Br2N6O2; C, 47.34; H, 3.25; N, 15.05%. Found: C, 47.21; H, 3.11; N, 14.91%. N-((6 S,7 S)-8-(2,6-Dichlorophenyl)-5-oxo-7-phenyl-2,3,5,6,7,8-hexahydroimidazo[1,2-a] pyrimidin-6-yl)acetamide (6a) White solid, MP: 287–289 °C, IR (KBr) (νmax/cm− 1); 3264(NH), 3062, 2938, 2881, 1695(C = O), 1647(C = O), 1545, 1459, 1429, 1400, 1292, 999, 783, 697; 1H NMR (300 MHz, DMSO-d6) δH (ppm) 1.64 (3 H, s, CH3), 3.60–3.65 (2 H, m, CH2), 3.76–3.85 (1H, m, CH2), 3.93–4.02 (1H, m, CH2), 4.93 (1H, dd, J = 9 Hz, J = 9 Hz, CH), 5.48 (1H, d, J = 12 Hz, CH), 7.11–7.16 (3 H, m, Ar-H), 7.27–7.33 (5 H, m, 4Ar-H, 1NH), 8.21–8.24 (1H, d, J = 9 Hz, Ar-H); 13C NMR (75 MHz, DMSO-d6) δC (ppm) 22.7, 44.2, 50.6, 54.6, 61.6, 128.2, 128.8, 128.9, 129.1, 129.3, 130.3, 134.6, 134.9, 136.0, 136.3, 150.1, 164.6, 169.6. LCMS m/z: 416 [M + H]+, 418 [M + H]2+. Anal.calcd. for: C20H18Cl2N4O2; C, 57.57; H, 4.35; N, 13.43%. Found: C, 57.45; H, 4.21; N, 13.30%. N-((6 S,7 S)-8-(2,6-Dichlorophenyl)-5-oxo-7-(p-tolyl)-2,3,5,6,7,8-hexahydroimidazo[1,2-a] pyrimidin-6-yl)acetamide (6b) White solid, MP: 286–289 °C, IR (KBr) (νmax/cm− 1) 3254(NH), 3057, 2872, 1701 (C = O), 1638 (C = O), 1547, 782; 1H NMR (300 MHz, DMSO-d6) δH (ppm) 1.65 (3 H, s, CH3), 2.15 (s, 3 H, CH3), 3.59–3.75 (2 H, m, CH2), 3.78–3.84 (1H, m, CH2), 3.93–4.02 (1H, m, CH2), 4.83 (1H, dd, J = 9 Hz, J = 12 Hz, CH), 5.45 (1H, d, J = 12 Hz, CH), 6.95–6.98 (2 H, d, J = 9 Hz, Ar-H), 7.12–7.21 (3 H, m, 2Ar-H, 1NH), 7.27–7.35 (2 H, m, Ar-H), 8.21 (1H, d, J = 9 Hz, Ar-H); 13C NMR (75 MHz, DMSO-d6) δC (ppm) 21.1, 22.7, 44.7, 50.5, 54.7, 61.3, 128.7, 128.9, 129.1, 130.3, 131.6, 134.9, 136.0, 136.3, 138.4, 150.1, 164.6, 169.6. LCMS m/z: 430 [M + H]+, 432 [M + H]2+. Anal.calcd. for: C21H20Cl2N4O2; C, 58.48; H, 4.67; N, 12.99%. Found: C, 58.33; H, 4.53; N, 12.85%. N-((6 S,7 S)-7-(4-Chlorophenyl)-8-(2,6-dichlorophenyl)-5-oxo-2,3,5,6,7,8-hexahydroimidazo [1,2-a]pyrimidin-6-yl)acetamide (6c) White solid, MP: 287–290 °C, IR (KBr) (νmax/cm− 1) 3262 (NH), 3049, 2939, 1697 (C = O), 1649 (C = O), 1539, 782; 1H NMR (300 MHz, DMSO-d6) δH (ppm) 1.66 (3 H, s, CH3), 3.42–3.65 (2 H, m, CH2), 3.76–3.85 (1H, m, CH2), 3.93–4.02 (1H, m, CH2), 4.92 (1H, dd, J = 9 Hz, J = 12 Hz, CH), 5.48 (1H, d, J = 12 Hz, CH), 7.16–7.21 (1H, m, Ar-H), 7.25–7.38 (6 H, m, 5Ar-H, 1NH), 8.24 (1H, d, J = 12 Hz, Ar-H); 13C NMR (75 MHz, DMSO-d6) δC (ppm) 22.7, 44.8, 50.6, 54.4, 61.0, 128.4, 129.0, 129.2, 130.5, 133.7, 133.8, 134.8, 135.8, 136.3, 150.0, 164.3, 169.7. LCMS m/z: 450 [M + H]+, 452 [M + H]2+. Anal.calcd. for: C20H17Cl3N4O2; C, 53.18; H, 3.79; N, 12.40%. Found: C, 53.02; H, 3.67; N, 12.27%. N-((6 S,7 S)-8-(2,6-Dichlorophenyl)-7-(4-nitrophenyl)-5-oxo-2,3,5,6,7,8-hexahydroimidazo [1,2-a]pyrimidin-6-yl)acetamide (6d) White solid, MP: 262–264 °C, IR (KBr) (νmax/cm− 1) 3253 (NH), 3053, 2864, 1772 (C = O), 1697 (C = O), 1649, 1539, 786; 1H NMR (300 MHz, DMSO-d6) δH (ppm) 1.66 (3 H, s, CH3), 3.62–3.79 (2 H, m, CH2), 3.82–3.88 (1H, m, CH2), 3.95–4.04 (m, 1H, CH2), 4.99 (1H, dd, J = 9 Hz, J = 9 Hz, CH), 5.65 (1H, d, J = 12 Hz, CH), 7.16–7.21 (1H, m, Ar-H), 7.31–7.38 (2 H, m, 1Ar-H, 1NH), 7.59–7.62 (2 H, m, Ar-H), 8.07–8.09 (1H, d, J = 6 Hz, Ar-H), 8.27–8.29 (1H, d, J = 6 Hz, Ar-H); 13C NMR (75 MHz, DMSO-d6) δC (ppm) 22.6, 44.9, 49.06, 50.6, 54.5, 61.0, 123.5, 129.2, 129.4, 130.4, 130.7, 134.6, 135.5, 136.3, 142.2, 148.0, 149.9, 163.9, 169.9. LCMS m/z: 461 [M + H]+, 463 [M + H]2+. Anal.calcd. for: C20H17Cl2N5O4; C, 51.96; H, 3.71; N, 15.15%. Found: C, 51.83; H, 3.60; N, 15.01%. N-((6 S,7 S)-8-(2,6-Dichlorophenyl)-7-(4-hydroxyphenyl)-5-oxo-2,3,5,6,7,8-hexahydroimidazo[1,2-a]pyrimidin-6-yl)acetamide (6e) White solid, MP: 241–243 °C, IR (KBr) (νmax/cm− 1) 3526 (OH), 3348 (NH), 3086, 1683 (C = O), 1642 (C = O),1528, 1433, 1280, 781; 1H NMR (400 MHz, DMSO-d6) δH (ppm) 1.67 (3 H, s, CH3), 3.35–3.66 (2 H, m, CH2), 3.75–3.82 (1H, m, CH2), 3.94–3.99 (m, 1H, CH2), 4.87 (1H, dd, J = 9 Hz, J = 12 Hz, CH), 5.34 (1H, d, J = 12 Hz, CH), 6.49–6.52 (2 H, d, J = 12 Hz, Ar-H), 7.09–7.18 (3 H, m, 2Ar-H, 1NH), 7.30–7.35 (2 H, m, Ar-H), 8.17–8.19 (1H, M, Ar-H), 9.41 (1H, s, OH); 13C NMR (100 MHz, DMSO-d6) δC (ppm) 21.1, 43.1, 48.9, 52.9, 59.6, 113.4, 123.0, 127.2, 127.4, 128.4, 128.5, 133.5, 134.6, 134.7, 148.5, 156.2, 163.2, 167.9. LCMS m/z: 432 [M + H]+, 434 [M + H]2+. Anal.calcd. for: C20H18Cl2N4O3; C, 55.44; H, 4.19; N, 12.93%. Found: C, 55.30; H, 4.04; N, 12.80%. N-((6 S,7 S)-8-(2,6-Dichlorophenyl)-5-oxo-7-(thiophen-2-yl)-2,3,5,6,7,8-hexahydroimidazo [1,2-a]pyrimidin-6-yl)acetamide (6f) White solid, MP: 279–281 °C, IR (KBr) (νmax/cm− 1) 3262 (NH), 3045, 2931, 1693 (C = O), 1645 (C = O), 1082, 786; 1H NMR (300 MHz, DMSO-d6) δH (ppm) 1.71 (3 H, s, CH3), 3.59–3.64 (2 H, m, CH2), 3.75–3.84 (1H, m, CH2), 3.92–4.01 (m, 1H, CH2), 4.81 (1H, dd, J = 9 Hz, J = 12 Hz, CH), 5.78 (1H, d, J = 12 Hz, CH), 6.81–6.83 (1H, t, J = 6 Hz, Ar-H), 7.05–7.07 (1H, d, J = 6 Hz, NH), 7.18–7.24 (1H, t, J = 9 Hz, Ar-H), 7.35–7.38 (3 H, m, 2Ar-H, 1NH), 8.33-0.35 (1H, d, J = 9 Hz, Ar-H); 13C NMR (75 MHz, DMSO-d6) δC (ppm) 22.7, 44.8, 50.6, 55.8, 56.3, 126.8, 127.7, 128.8, 128.9, 129.0, 130.5, 135.3, 135.6, 136.7, 136.9, 149.5, 163.9, 169.8. LCMS m/z: 422 [M + H]+, 424 [M + H]2+. Anal.calcd. for: C18H16Cl2N4O2S; C, 51.07; H, 3.81; N, 13.24. Found: C, 50.92; H, 3.70; N, 13.10. N-((6 S,7 S)-7-(4-Bromophenyl)-8-(2,6-dichlorophenyl)-5-oxo-2,3,5,6,7,8-hexahydroimidazo [1,2-a]pyrimidin-6-yl)acetamide (6 g) White solid, MP: 277–279 °C, IR (KBr) (νmax/cm− 1) 3258(NH), 3049, 1701(C = O), 1649 (C = O), 1291, 790; 1H NMR (300 MHz, DMSO-d6) δH (ppm) 1.66 (3 H, s, CH3), 3.60–3.65 (2 H, m, CH2), 3.76–3.82 (1H, m, CH2), 3.93–3.99 (1H, m, CH2), 4.90 (1H, dd, J = 3 Hz, J = 9 Hz, CH), 5.47 (1H, d, J = 12 Hz, CH), 7.16–7.27 (3 H, m, 2Ar-H, 1NH), 7.31–7.42 (4 H, m, Ar-H), 8.25 (1H, m, Ar-H); 13C NMR (75 MHz, DMSO-d6) δC (ppm) 22.7, 44.8, 50.6, 54.4, 61.0, 122.5, 129.0, 129.2, 130.5, 130.9, 131.3, 134.1, 134.8, 135.7, 136.3, 150.0, 164.3, 169.7. LCMS m/z: 494 [M + H]+, 496 [M + H]2+. Anal.calcd. for: C20H17BrCl2N4O2; C, 48.41; H, 3.45; N, 11.29. Found: C, 48.29; H, 3.31; N, 11.14. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Author contributions Ali Asghar Mohammadi conceived of the presented idea and supervised the findings of this work. Keikavoos Rahmati carried out the experiment. Mohammad Reza Halvgar carried out the Single-Crystal X-ray Diffraction.CCDC: 4 g= 2216250, 6d =2216249. Vahid Amani performed the Single-Crystal characterization, aided in interpreting and the ORTEP and crystal packing diagram for Figs. 2 and 3, S1, S2, S3 and S4. These figures were drawn with the Mercury 2.4 software (Mercury 141. Copyright Cambridge Crystallographic Data Center. Cambridge, 2001-2005). All images are drawn by us and are not used anywhere. All authors discussed the results and contributed to the final manuscript. Funding The authors declare that no funds, grants, or other support were received during the preparation of this manuscript. Data availability All data gathered during this study are included in this published article, with the exception of the FCF files. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Data Availability Statement All data gathered during this study are included in this published article, with the exception of the FCF files.